Fromen to leave PacBio as CCO
Plus Vraniak joins Inversago as CFO and updates from Thabor, Glympse, Civetta and more
Pacific Biosciences of California Inc. (NASDAQ:PACB) announced the resignation of chief commercial officer Peter Fromen, effective May 20, in an SEC filing. Fromen joined the company in 2021 from Illumina Inc. (NASDAQ:ILMN), and is leaving to pursue new opportunities. Until a successor is named, President and CEO Christian Henry, and VP of Customer Experience Chris Seipert will take over PacBio’s marketing responsibilities, and sales, service and support responsibilities, respectively.
Inversago Pharma Inc. hired Glenn Vraniak as CFO. Vraniak led IPOs at Evaxion Biotech A/S (NASDAQ:EVAX) and electroCore Inc., during his term as CFO. He has also served as an executive in various companies, including GE Capital. Inversago is developing peripherally acting CB1 inverse agonists to treat metabolic conditions...